Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EHVA

Financiado

Cerrado

European HIV Vaccine Alliance EHVA a EU platform for the discovery and evalua...

European HIV Vaccine Alliance EHVA a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity a... ver más

31/12/2023

INSERM

28M€

Presupuesto del proyecto: 28M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 49 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-31

PHC-09-2015: PHC 9 – 2015: Vaccine development f...

I+D

Cerrada hace 9 años

0% 79% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

49 Participantes

INSERM

2.12M€ | Lider

INFORMATICA 68

714.52K€ | Participante

UDUS

50.00K€ | Participante

UNIVERSITY COLLEGE LONDON

2.51M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

SAF2015-66193-R UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA... 182K€ Cerrado

SAF2013-45232-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA... 593K€ Cerrado

UNFITHIV Understanding the importance of viral Fitness Impairment aft... 279K€ Cerrado

CUT'HIVAC Cutaneous and Mucosal HIV Vaccination 15M€ Cerrado

DynOMIS Dynamic Origins of MHC class I Selector function 195K€ Cerrado

Duración del proyecto: 96 meses Fecha Inicio: 2015-12-17
Fecha Fin: 2023-12-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 28M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores